1. Covering the Cover Gastroenterology
Anson W. Lowe, Richard H. Moseley 
Gastroenterology 
Volume 143, Issue 6, Pages (December 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1 Absolute weekly change in parenteral support.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
Immunohistochemistry of ACTG2 protein in the intestinal muscle of a wild-type control (A) and an affected ACTG2 R148S patient (B). The right arrow in (B) highlights an inclusion body of ACTG2 protein within the muscle of an affected patient that contrasts with the diffuse staining observed in the wild type (A). The scale bars represent 50 μm.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

4. Figure 3
Interval development of first episode of acute pancreatitis during follow-up. BES, biliary endoscopic sphincterotomy; DES, dual endoscopic sphincterotomy; RAP, recurrent acute pancreatitis; SOM, sphincter of Oddi manometry.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

5. Figure 4
Sorafenib increases invasiveness and metastatic potential in the LM3-RFP orthotopic hepatocellular carcinoma model. (A) Median survival and tumor size in tumor-bearing mice treated with sorafenib compared with controls. (B) Number of lung metastases and standardized number of lung metastases (SNLM) in tumor-bearing mice treated with sorafenib compared with controls. (C) Percentage of circulating tumor cells in tumor-bearing mice treated with sorafenib compared with controls. (D) Number of intrahepatic metastases (IHM; arrows) by bright field (b) and fluorescence (f) stereomicroscopy and hematoxylin and eosin staining in tumor-bearing mice treated with sorafenib compared with controls.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions